Skip to content
Research Article Open access CC BY 4.0

Sacubitril/Valsartan as a New Possible Therapeutic Alternative for the Treatment of Hypertension

Anish Desai, Sunaina Anand, Prachi Sanghvi, Aanchal Gvalani, Priyanka Das

Asian Journal of Cardiology Research · pp. 437–441 · Published 30 Dec 2023

Abstract

Hypertension, a major modifiable risk factor for cardiovascular disease and global mortality, affects approximately 31.1% of adults worldwide. Resistant hypertension, observed in 13-30% of hypertensive patients, poses a challenge in treatment escalation, contributing to clinical inertia. Sacubitril/valsartan, a dual-action compound comprising valsartan (an angiotensin receptor blocker) and sacubitril (a neprilysin inhibitor), has garnered approval in China and Japan for Hypertension and FDA approval for heart failure. This article aims to review the possibility of sacubitril/ valsartan as an alternative therapy for the treatment of hypertension. Clinical evidence indicates sacubitril/valsartan's efficacy in reducing blood pressure. Notably, it also demonstrates significant blood pressure reductions in patients with heart failure, emphasizing its dual benefits. The compound's superior efficacy in improving hypertension and left ventricular hypertrophy is a focus of ongoing investigations. This review highlights the role of sacubitril/valsartan as a promising therapeutic option for the management of hypertension.

Blood pressure hypertension sacubitril/valsartan

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.